Timing of Venous Thromboembolism Prophylaxis in Patients with Hypertensive Intracerebral Hemorrhage
Launched by PIROGOV RUSSIAN NATIONAL RESEARCH MEDICAL UNIVERSITY · Dec 22, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the best timing for starting a medication called heparin, which helps prevent serious blood clots, in patients who have experienced a type of brain bleed known as hypertensive intracerebral hemorrhage. Researchers want to find out if starting heparin early, within the first two days of hospital admission, is safer and more effective than starting it on the third day. They will look closely at how well patients do and whether they experience any complications, such as bleeding.
To participate in the trial, patients must have a diagnosis of hypertensive intracerebral hemorrhage but must not show signs of bleeding worsening within the first day or have other specific health issues, like cancer or recent surgeries. Participants will receive regular brain scans and ultrasound exams of their legs during their hospital stay to monitor their condition. This study aims to ensure that patients receive the best possible care while minimizing risks associated with both blood clots and bleeding.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • the presence of hypertensive intracerebral hemorrhage
- Exclusion Criteria:
- • Intracerebral hemorrhage expansion detected on the basis of a computed tomography scan of the brain 12-24 hours after a hospital admission (i.e. before the initiation of venous thromboembolism prophylaxis with heparin)
- • Being on an anticoagulant during preadmission period and on day of hospital admission
- • Death within the first 2 days after hospital admission
- • Detection of venous thromboembolism in a patient at the moment of hospital admission
- • Surgical management of hypertensive intracerebral hemorrhage before the beginning of venous thromboembolism prophylaxis using heparin
- • The presence of a malignancy (cancer) in a patient at the moment of hospital admission
About Pirogov Russian National Research Medical University
Pirogov Russian National Research Medical University is a prestigious academic institution dedicated to advancing medical science and education in Russia. Renowned for its commitment to high-quality research and innovation, the university plays a pivotal role in clinical trials aimed at improving healthcare outcomes. With a multidisciplinary approach, it fosters collaboration among leading experts in various medical fields, ensuring the development of safe and effective therapeutic interventions. The institution is focused on translating research findings into clinical practice, thereby contributing significantly to the advancement of medical knowledge and patient care both nationally and internationally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Moscow, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported